Research programme: cyclin-dependent kinase 4 inhibitors - Wyeth
Latest Information Update: 28 Sep 2011
At a glance
- Originator Wyeth
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Oct 2009 Wyeth has been acquired by Pfizer
- 14 May 2007 Preclinical trials in Cancer in USA (unspecified route)